Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMO Awarded $213.9 Mil. In Patent Case Ruling, But Alcon Will Appeal

This article was originally published in The Gray Sheet

Executive Summary

A recent patent infringement ruling in favor of Advanced Medical Optics buttresses the firm's competitive position as it prepares to launch a new version of its Sovereign phacoemulsification system in 2007, according to the company

You may also be interested in...



Advanced Medical Optics And Alcon Leave Courtroom Behind

Advanced Medical Optics and Alcon, facing the prospect of long-term litigation costs, settled all of their outstanding patent disputes relating to ophthalmic surgery July 10 in an agreement where Alcon will pay AMO $121 mil

Advanced Medical Optics And Alcon Leave Courtroom Behind

Advanced Medical Optics and Alcon, facing the prospect of long-term litigation costs, settled all of their outstanding patent disputes relating to ophthalmic surgery July 10 in an agreement where Alcon will pay AMO $121 mil

JP Morgan Healthcare Conference In Brief

FoxHollow files IDE for coronary indication: Plaque excision system manufacturer filed an IDE to resume a clinical trial studying the use of SilverHawk to treat coronary artery disease in type B and C bifurcation lesions on Jan. 9, the company announced at the JP Morgan Healthcare conference in San Francisco. The initial study, begun in Oct. 2002, was shelved in Dec. 2003 due to adverse events observed in a subset of the patients (1"The Gray Sheet" Nov. 1, 2004, p. 20). Enrollment for the 250-patient trial is expected to begin in the second quarter, interim CEO John Simpson, MD/PhD said. FoxHollow also plans to initiate a 100-patient randomized, controlled trial comparing treatment with SilverHawk to medical management for peripheral artery disease, the device's approved indication. The Redwood City, Calif. firm hopes the trial results will accelerate the firm's quest for profitability, a goal that has been delayed by an $11.4 mil. stock-based compensation expense this quarter related to the departure of CEO Robert Thomas Jan. 1 (2"The Gray Sheet" Jan. 9, 2006, p. 13)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT023045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel